3/7
12:26 pm
cgem
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $35.00 price target on the stock, down previously from $38.00.
Low
Report
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $35.00 price target on the stock, down previously from $38.00.
2/28
08:13 am
cgem
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $33.00 price target on the stock.
High
Report
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $33.00 price target on the stock.
2/27
07:00 am
cgem
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Low
Report
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
2/24
07:00 am
cgem
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
1/30
07:00 am
cgem
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
Medium
Report
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
1/29
01:21 pm
cgem
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its price target raised by analysts at HC Wainwright from $28.00 to $33.00. They now have a "buy" rating on the stock.
Medium
Report
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its price target raised by analysts at HC Wainwright from $28.00 to $33.00. They now have a "buy" rating on the stock.
1/28
07:00 pm
cgem
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy
Medium
Report
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy